These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 8838775)

  • 1. The assessment of individual and population bioequivalence.
    Chinchilli VM
    J Biopharm Stat; 1996 Mar; 6(1):1-14. PubMed ID: 8838775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The analysis of bioequivalence with respect to TMAX under a 2 x 2 crossover design.
    Have TR; Ten Chinchilli VM
    J Biopharm Stat; 1995 Jul; 5(2):185-99. PubMed ID: 7581427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of multiple-dose bioequivalence studies.
    Chinchilli VM; Esinhart JD; Barr WH
    J Biopharm Stat; 1994 Nov; 4(3):423-35. PubMed ID: 7881454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tests for individual and population bioequivalence based on generalized p-values.
    McNally RJ; Iyer H; Mathew T
    Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On assessment of bioequivalence under a higher-order crossover design.
    Chow SC; Liu JP
    J Biopharm Stat; 1992; 2(2):239-56. PubMed ID: 1300216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The subject-by-formulation interaction in multivariate bioequivalence.
    Cao L; Mathew T
    J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extension to the use of tolerance intervals for the assessment of individual bioequivalence.
    Esinhart JD; Chinchilli VM
    J Biopharm Stat; 1994 Mar; 4(1):39-52. PubMed ID: 8019583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of outlying subjects on decision of bioequivalence.
    Ki FY; Liu JP; Wang W; Chow SC
    J Biopharm Stat; 1995 Mar; 5(1):71-94. PubMed ID: 7613561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Average bioequivalence for two-sequence two-period crossover design with incomplete data.
    Lee JY; Kim BC; Park SG
    J Biopharm Stat; 2005; 15(5):857-67. PubMed ID: 16078389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A three-step procedure for assessing bioequivalence in the general mixed model framework.
    Vuorinen J; Turunen J
    Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing individual bioequivalence using the structural equation model.
    Carrasco JL; Jover L
    Stat Med; 2003 Mar; 22(6):901-12. PubMed ID: 12627408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
    Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
    Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study].
    Heintz B; Müller A; Lenhard G; Schütz M; Hutt HJ
    Arzneimittelforschung; 1996 Nov; 46(11):1060-3. PubMed ID: 9065315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study on the bioequivalence of an oral nifedipine formulation and a sustained release reference preparation after single dose and repeated doses.
    Tröger U; Martens J; Meyer FP; Hoffmann A; Terhaag B
    Arzneimittelforschung; 1995 Dec; 45(12):1266-70. PubMed ID: 8595082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new approach for outliers in a bioavailability/bioequivalence study.
    Liao JJ
    J Biopharm Stat; 2007; 17(3):393-405. PubMed ID: 17479389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing bioequivalence using genomic data.
    Chow SC; Shao J; Li L
    J Biopharm Stat; 2004 Nov; 14(4):869-80. PubMed ID: 15587969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Types of bioequivalence and related statistical considerations.
    Hauck WW; Anderson S
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A distribution-free procedure for the statistical analysis of bioequivalence studies.
    Hauschke D; Steinijans VW; Diletti E
    Int J Clin Pharmacol Ther Toxicol; 1990 Feb; 28(2):72-8. PubMed ID: 2307548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
    Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
    Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.